Chikungunya Vaccine Market Research Reportβ€”Global Forecast till 2030

Chikungunya Vaccine Market Research Report Information By Product Technology (Live-Attenuated Virus Vaccines, Inactivated Viral Vaccine, Recombinant Viral Vaccines, Chimeric-Alphavirus Candidates and Others), By Age Group (Pediatric, Adult and Geriatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2030

ID: MRFR/HC/9547-CR | 141 Pages | Author: Kinjoll Dey | November 2022         

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.4 FORECASTING TECHNIQUES

3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.5.1 BOTTOM-UP APPROACH

3.5.2 TOP-DOWN APPROACH

3.6 DATA TRIANGULATION

3.7 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 RISING PREVALENCE OF CHIKUNGUNYA FEVER

4.2.2 INCREASING AWARENESS ABOUT MOSQUITO-TRANSMITTED INFECTIONS

4.2.3 INCREASING GOVERNMENT INITIATIVES REGARDING PREVENTION AND CONTROL OF CHIKUNGUNYA

4.3 RESTRAINTS

4.3.1 STRINGENT REGULATORY REQUIREMENTS

4.4 OPPORTUNITIES

4.4.1 RISING UNMET NEEDS FOR CHIKUNGUNYA TREATMENT IN DEVELOPING AND UNDERDEVELOPED COUNTRIES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D AND DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION, MARKETING, AND SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 BARGAINING POWER OF SUPPLIERS

5.2.2 BARGAINING POWER OF BUYERS

5.2.3 THREAT OF NEW ENTRANTS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT ANALYSIS OF COVID-19 ON CHIKUNGUNYA VACCINE MARKET

5.3.1 OVERVIEW

5.3.2 IMPACT ON SUPPLY CHAIN

5.3.3 IMPACT ON CLINICAL TRIALS

6 GLOBAL CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY

6.1 INTRODUCTION

6.2 LIVE-ATTENUATED VIRUS VACCINES

6.3 INACTIVATED VIRAL VACCINE

6.4 RECOMBINANT VIRAL VACCINES

6.5 CHIMERIC-ALPHAVIRUS CANDIDATES

6.6 OTHERS

7 GLOBAL CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP

7.1 INTRODUCTION

7.2 PEDIATRIC

7.3 ADULT

7.4 GERIATRIC

8 GLOBAL CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL

8.1 INTRODUCTION

8.2 HOSPITAL PHARMACIES

8.3 RETAIL PHARMACIES

8.4 OTHERS

9 GLOBAL CHIKUNGUNYA VACCINE MARKET, BY REGION

9.1 NORTH AMERICA

9.1.1 US

9.1.2 CANADA

9.2 EUROPE

9.2.1 GERMANY

9.2.2 UK

9.2.3 FRANCE

9.2.4 ITALY

9.2.5 SPAIN

9.2.6 REST OF EUROPE

9.3 ASIA-PACIFIC

9.3.1 CHINA

9.3.2 INDIA

9.3.3 JAPAN

9.3.4 AUSTRALIA

9.3.5 SOUTH KOREA

9.3.6 REST OF ASIA-PACIFIC

9.4 REST OF THE WORLD

9.4.1 MIDDLE EAST

9.4.2 AFRICA

9.4.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 MAJOR PLAYERS SALES ANALYSIS

10.3.1 SALES

10.4 MAJOR PLAYERS R&D ANALYSIS

11 COMPANY PROFILES

11.1 TAKEDA PHARMACEUTICAL COMPANY LIMITED

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 THERMIS BIOSCIENCE GMBH

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 KEY STRATEGIES

11.3 AURO VACCINES LLC.

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 KEY STRATEGIES

11.4 MODERNA, INC.

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 VALNEVA AUSTRIA GMBH

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 SWOT ANALYSIS

11.5.6 KEY STRATEGIES

11.6 EMERGENT BISOLUTIONS INC.

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.6.6 KEY STRATEGIES

11.7 BHARAT BIOTECH INTERNATIONAL LIMITED

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 SWOT ANALYSIS

11.7.6 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 GLOBAL CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 3 GLOBAL CHIKUNGUNYA VACCINE MARKET, FOR LIVE-ATTENUATED VIRUS VACCINES, BY REGION, 2018–2030 (USD MILLION)

TABLE 4 GLOBAL CHIKUNGUNYA VACCINE MARKET, FOR INACTIVATED VIRAL VACCINE, BY REGION, 2018–2030 (USD MILLION)

TABLE 5 GLOBAL CHIKUNGUNYA VACCINE MARKET, FOR RECOMBINANT VIRAL VACCINES, BY REGION, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL CHIKUNGUNYA VACCINE MARKET, FOR CHIMERIC-ALPHAVIRUS CANDIDATES, BY REGION, 2018–2030 (USD MILLION)

TABLE 7 GLOBAL CHIKUNGUNYA VACCINE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 8 GLOBAL CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 9 GLOBAL CHIKUNGUNYA VACCINE MARKET, FOR PEDIATRIC, BY REGION, 2018–2030 (USD MILLION)

TABLE 10 GLOBAL CHIKUNGUNYA VACCINE MARKET, FOR ADULT, BY REGION, 2018–2030 (USD MILLION)

TABLE 11 GLOBAL CHIKUNGUNYA VACCINE MARKET, FOR GERIATRIC, BY REGION, 2018–2030 (USD MILLION)

TABLE 12 GLOBAL CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 13 GLOBAL CHIKUNGUNYA VACCINE MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2018–2030 (USD MILLION)

TABLE 14 GLOBAL CHIKUNGUNYA VACCINE MARKET, FOR RETAIL PHARMACIES, BY REGION, 2018–2030 (USD MILLION)

TABLE 15 GLOBAL CHIKUNGUNYA VACCINE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 16 GLOBAL: CHIKUNGUNYA VACCINE MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 17 GLOBAL: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 18 GLOBAL: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 19 GLOBAL: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 20 NORTH AMERICA: CHIKUNGUNYA VACCINE MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 21 NORTH AMERICA: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 22 NORTH AMERICA: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 23 NORTH AMERICA: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 24 US: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 25 US: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 26 US: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 27 CANADA: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 28 CANADA: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 29 CANADA: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 30 EUROPE: CHIKUNGUNYA VACCINE MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 31 EUROPE: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 32 EUROPE: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 33 EUROPE: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 34 GERMANY: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 35 GERMANY: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 36 GERMANY: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 37 UK: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 38 UK: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 39 UK: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 40 FRANCE: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 41 FRANCE: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 42 FRANCE: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 43 ITALY CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 44 ITALY: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 45 ITALY: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 46 SPAIN: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 47 SPAIN: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 48 SPAIN: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 49 REST OF EUROPE: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 50 REST OF EUROPE: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 51 REST OF EUROPE: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC: CHIKUNGUNYA VACCINE MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 54 ASIA-PACIFIC: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 55 ASIA-PACIFIC: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 56 CHINA: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 57 CHINA: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 58 CHINA: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 59 INDIA: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 60 INDIA: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 61 INDIA: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 62 JAPAN: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 63 JAPAN: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 64 JAPAN: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 65 AUSTRALIA: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 66 AUSTRALIA: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 67 AUSTRALIA: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 68 SOUTH KOREA: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 69 SOUTH KOREA: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 70 SOUTH KOREA: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 71 REST OF ASIA-PACIFIC: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 72 REST OF ASIA-PACIFIC: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 73 REST OF ASIA-PACIFIC: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 74 REST OF THE WORLD: CHIKUNGUNYA VACCINE MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 75 REST OF THE WORLD: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 76 REST OF THE WORLD: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 77 REST OF THE WORLD: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 78 MIDDLE EAST: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 79 MIDDLE EAST: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 80 MIDDLE EAST: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 81 AFRICA: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 82 AFRICA: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 83 AFRICA: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 84 LATIN AMERICA: CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 85 LATIN AMERICA: CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2018–2030 (USD MILLION)

TABLE 86 LATIN AMERICA: CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 87 MAJOR MANUFACTURERS IN CHIKUNGUNYA VACCINE MARKET

TABLE 88 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED

TABLE 89 THERMIS BIOSCIENCE GMBH: PRODUCTS OFFERED

TABLE 90 AURO VACCINES LLC: PRODUCTS OFFERED

TABLE 91 MODERNA, INC.: PRODUCTS OFFERED

TABLE 92 VALNEVA AUSTRIA GMBH: PRODUCTS OFFERED

TABLE 93 EMERGENT BIOSOLUTIONS INC: PRODUCTS OFFERED

TABLE 94 BHARAT BIOTECH INTERNATIONAL LIMITED: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 GLOBAL CHIKUNGUNYA VACCINE MARKET STRUCTURE

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 3 MARKET DYNAMICS: GLOBAL CHIKUNGUNYA VACCINE MARKET

FIGURE 4 DRIVERS: IMPACT ANALYSIS

FIGURE 5 RESTRAINT: IMPACT ANALYSIS

FIGURE 6 VALUE CHAIN ANALYSIS: GLOBAL CHIKUNGUNYA VACCINE MARKET

FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL CHIKUNGUNYA VACCINE MARKET

FIGURE 8 SUMMARY OF SEGMENT-WISE ATTRACTIVENESS

FIGURE 9 GLOBAL CHIKUNGUNYA VACCINE MARKET, BY TECHNOLOGY, 2021 & 2030 (USD MILLION)

FIGURE 10 GLOBAL CHIKUNGUNYA VACCINE MARKET SHARE, BY TECHNOLOGY, 2021 (%)

FIGURE 11 SUMMARY OF SEGMENT-WISE ATTRACTIVENESS

FIGURE 12 GLOBAL CHIKUNGUNYA VACCINE MARKET, BY AGE GROUP, 2021 & 2030 (USD MILLION)

FIGURE 13 GLOBAL CHIKUNGUNYA VACCINE MARKET SHARE, BY AGE GROUP, 2021 (%)

FIGURE 14 SUMMARY OF SEGMENT-WISE ATTRACTIVENESS

FIGURE 15 GLOBAL CHIKUNGUNYA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2021 & 2030 (USD MILLION)

FIGURE 16 GLOBAL CHIKUNGUNYA VACCINE MARKET SHARE, BY DISTRIBUTION CHANNEL, 2021 (%)

FIGURE 17 GLOBAL CHIKUNGUNYA VACCINE MARKET, BY REGION, 2021 & 2030 (USD MILLION)

FIGURE 18 GLOBAL: CHIKUNGUNYA VACCINE MARKET SHARE (%), BY REGION 2021

FIGURE 19 NORTH AMERICA MARKET ANALYSIS CHIKUNGUNYA VACCINE MARKET, 2021-2030 (USD MILLION)

FIGURE 20 NORTH AMERICA: CHIKUNGUNYA VACCINE MARKET SHARE (%), BY REGION 2021

FIGURE 21 EUROPE MARKET ANALYSIS CHIKUNGUNYA VACCINE MARKET, 2021-2030 (USD MILLION)

FIGURE 22 EUROPE: CHIKUNGUNYA VACCINE MARKET SHARE (%), BY REGION 2021

FIGURE 23 ASIA-PACIFIC MARKET ANALYSIS CHIKUNGUNYA VACCINE MARKET, 2021-2030 (USD MILLION)

FIGURE 24 ASIA-PACIFIC: CHIKUNGUNYA VACCINE MARKET SHARE (%), BY COUNTRY, 2021

FIGURE 25 REST OF THE WORLD MARKET ANALYSIS CHIKUNGUNYA VACCINE MARKET, 2021-2030 (USD MILLION)

FIGURE 26 REST OF THE WORLD: CHIKUNGUNYA VACCINE MARKET SHARE (%), BY COUNTRY, 2021

FIGURE 27 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 28 MAJOR PLAYERS SALES, 2021

FIGURE 29 MAJOR PLAYERS R&D EXPENDITURE, 2021

FIGURE 30 TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 TAKEDA PHARMACEUTICAL COMPANY LIMITED: SWOT ANALYSIS

FIGURE 32 MODERNA, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 MODERNA, INC.: SWOT ANALYSIS

FIGURE 34 VALNEVA AUSTRIA GMBH: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 VALNEVA AUSTRIA GMBH: SWOT ANALYSIS

FIGURE 36 EMERGENT BISOLUTIONS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 EMERGENT BIOSOLUTIONS INC.: SWOT ANALYSIS

FIGURE 38 BHARAT BIOTECH INTERNATIONAL LIMITED: SWOT ANALYSIS

Market Segmentation


Chikungunya Vaccine Product Technology Outlook (USD Billion, 2019-2030)




  • Live-Attenuated Virus Vaccines




  • Inactivated Viral Vaccine




  • Recombinant Viral Vaccines




  • Chimeric-Alphavirus Candidates




  • Others




Chikungunya Vaccine Age Group Outlook (USD Billion, 2019-2030)




  • Pediatric




  • Adult




  • Geriatric




Chikungunya Vaccine Distrubition ChannelOutlook (USD Billion, 2019-2030)




  • Hospital Pharmacies




  • Retail Pharmacies




  • Others




Chikungunya Vaccine Regional Outlook (USD Billion, 2019-2030)




  • North America Outlook (USD Billion, 2019-2030)




    • North America Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • North America Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • North America Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






    • US Outlook (USD Billion, 2019-2030)




    • US Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • US Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • US Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






    • CANADA Outlook (USD Billion, 2019-2030)




    • CANADA Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • CANADA Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • CANADA Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others








  • Europe Outlook (USD Billion, 2019-2030)




    • Europe Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • Europe Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • Europe Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






    • Germany Outlook (USD Billion, 2019-2030)




    • Germany Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • Germany Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • Germany Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






    • France Outlook (USD Billion, 2019-2030)




    • France Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • France Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • France Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






    • UK Outlook (USD Billion, 2019-2030)




    • UK Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • UK Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • UK Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






    • ITALY Outlook (USD Billion, 2019-2030)




    • ITALY Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • ITALY Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • ITALY Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others














    • SPAIN Outlook (USD Billion, 2019-2030)




    • Spain Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • Spain Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • Spain Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






    • Rest Of Europe Outlook (USD Billion, 2019-2030)




    • Rest Of Europe Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • REST OF EUROPE Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • REST OF EUROPE Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others







  • Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Asia-Pacific Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • Asia-Pacific Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • Asia-Pacific Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others














    • China Outlook (USD Billion, 2019-2030)




    • China Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • China Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • China Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






    • Japan Outlook (USD Billion, 2019-2030)




    • Japan Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • Japan Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • Japan Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






    • India Outlook (USD Billion, 2019-2030)




    • India Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others













    • India Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • India Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






    • Australia Outlook (USD Billion, 2019-2030)




    • Australia Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • Australia Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • Australia Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Rest of Asia-Pacific Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • Rest of Asia-Pacific Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • Rest of Asia-Pacific Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others







  • Rest of the World Outlook (USD Billion, 2019-2030)




    • Rest of the World Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • Rest of the World Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • Rest of the World Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others














    • Middle East Outlook (USD Billion, 2019-2030)




    • Middle East Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • Middle East Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • Middle East Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






    • Africa Outlook (USD Billion, 2019-2030)




    • Africa Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • Africa Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • Africa Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






    • Latin America Outlook (USD Billion, 2019-2030)




    • Latin America Chikungunya Vaccine by Product Technology




      • Live-Attenuated Virus Vaccines




      • Inactivated Viral Vaccine




      • Recombinant Viral Vaccines




      • Chimeric-Alphavirus Candidates




      • Others






    • Latin America Chikungunya Vaccine by Age Group




      • Pediatric




      • Adult




      • Geriatric






    • Latin America Chikungunya Vaccine by Distrubition Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Others






Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid